Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.29 -1.74%

-$0.25 today

Market cap
$629.58M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.65M

Average 1.02M

Returns on capital

Janux Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-11.9%

avg 5.1%

ROIC

-16.0%

avg -1051.8%

ROA

-11.3%

avg -103.6%

Analysis

ROA is currently the strongest return metric at -11.3% versus its period average of -103.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David Alan Campbell

President, Co-Founder, CEO & DirectorUSD 1.05M66264.74K0.43%

Thomas Diraimondo

Chief Scientific OfficerUSD 653.9K40109.90K0.18%

Charles Winter

Chief Technical OfficerUSD 590.4K57——

Janeen Doyle

Chief Corporate & Business Development OfficerUSD 549.03K48——

James Pennington

General Counsel & Corporate Secretary————

Matt Whitmire

Vice President of Finance————

Mandie Forman-Sklansky

Head of Human Resources————

Maria Dobek

Vice President of Accounting—3632.27K0.05%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 31, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

10

$457,074.36

Net Transaction Value

−$457,074.36

Net selling

Most Active

Meyer Andrew Hollman

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 2, 26

Doyle Janeen Noel

Direct

Sell$56.9K
May 11, 26

Dobek Maria

Direct

Sell$28.9K
Jan 2, 26

Meyer Andrew Hollman

Direct

Sell$25.8K
Jan 2, 26

DiRaimondo Thomas

Direct

Sell$34.4K
Jan 2, 26

Campbell David Alan

Direct

Sell$110.8K
Jan 2, 26

Winter Charles M.

Direct

Sell$33K
Jan 2, 26

McIver Zachariah

Direct

Sell$37.3K
Jan 2, 26

Dobek Maria

Direct

Sell$20.1K
Dec 1, 25

Meyer Andrew Hollman

Direct

Sell$88.7K
Dec 1, 25

Meyer Andrew Hollman

Direct

Sell$21.2K

Summary

Insiders reported 0 buys worth $0.00 and 10 sells worth $457,074.36 over the last 12 months. That adds up to net selling of $457,074.36. Meyer Andrew Hollman was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+5.1%
+61.4% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +5.1% over three years. Forward estimates point to Revenue at +61.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Janux Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about JANX's management, answered from reported figures.

Who manages JANX?

Janux Therapeutics, Inc. (JANX) lists 8 active executives. The top listed executive is Charles Winter, Chief Technical Officer.

Are JANX insiders buying or selling?

Recent insider activity shows net buying of $35.94M.